LY3200882 + LY3300054

LY3200882 + LY3300054 is a combination investigational therapy comprising LY3200882, an oral, selective, next-generation small molecule inhibitor targeting the serine-threonine kinase domain of transforming growth factor beta receptor type-1 (TGFβR1), and LY3300054, a monoclonal antibody targeting programmed death ligand-1 (PD-L1). LY3200882 works by competitively inhibiting ATP binding to TGFβR1, thereby blocking TGFβ signaling, which plays a key role in immune evasion and tumor progression. LY3300054 inhibits PD-L1, thereby preventing PD-L1-mediated immune suppression, thus potentially amplifying anti-tumor immune responses. This drug combination has been evaluated in early-phase trials for advanced solid tumors, including grade 4 glioma and other cancers known to be refractory to immune checkpoint blockade. It is being developed by Eli Lilly[1][2][3].